Sinexus gets $20M, Entellus takes $15M for sinus products
Feeling stuffy? Two sinus-focused companies, Palo Alto, Calif.-based Sinexus and Maple Grove, Minn.-based Entellus, want to help out, with fresh rounds of funding for product development.
Venture funding for ear, nose & throat (ENT) companies hasn’t been terribly common in the past, but seems to be on the rise, with companies like these two and Acclarent, which took $35 million last year, promising safer, easier treatments for common sinus conditions. Acclarent just filed for an $86.25 million IPO, in fact, which may attract more attention to the ENT scene.
Sinexus is on its second funding, and is working on an unannounced consumer product to treat chronic sinusitis, according to VentureWire, which first spotted both investments. The $20 million round was led by PTV Sciences, with participation from Kleiner Perkins and U.S. Venture Partners. We reported its first round of $3.5 million last September.
Entellus is working on a surgical device for use in endoscopic surgery for treatment of chronic rhinosinusitis. Where the Sinexus device is still in early testing stages, the FinESS Sinus Treatment by Entellus just received FDA clearance. Its $15 million round was led by Montagu Newhall Associates, with Split Rock Partners and SV Life Sciences joining.
Next Story: Meebo introduces interactive ads, another step towards social web sites making money
Previous Story: Sense Networks experiments with indexing the city
About the Author, Chris Morrison
Chris Morrison writes about cleantech and environmental issues for VentureBeat, with occasional forays into gaming and semantic technology. He got his start writing about tech for Business 2.0 magazine, but quickly realized new media was the ticket when that institution closed its doors in 2007. Chris has also covered public equities and regulatory issues. He originally hails from southern Virginia, graduated from Evergreen State College in Washington, and now lives in San Francisco.